Back to search

Article

Rapid and cost-effective development of stable clones for the production of anti-Ebola monoclonal antibodies in HEK293T cells

2020-04-23

Abstract excerpt

The Ebola virus (EBOV) disease has caused serious and recurrent epidemics in recent years, resulting in a fatality rate of nearly 50%. The most effective experimental therapy against the EBOV is the use of monoclonal antibodies (mAbs). In this work, we describe the development of HEK293T cells engineered for the transient and stable expression of mAb13C6, a neutralizing anti-EBOV monoclonal antibody. We transfecte...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
1ea00e25-70f8-53bf-921d-7aa9a10a9f9e
DOI
10.1101/2020.04.21.054429
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Rapid and cost-effective development of stable clones for the production of anti-Ebola monoclonal antibodies in HEK293T cellsDOI 10.1101/2020.04.21.054429
Select a neighboring publication to make it the new centre.